Introduction
Acute ischemic stroke and transient ischemic attack (TIA) are medical emergencies that require prompt intervention to prevent recurrent events and reduce the risk of long-term disability. Dual antiplatelet therapy (DAPT) with clopidogrel (Plavix) and aspirin has been shown to be effective in secondary prevention, particularly when initiated early. This article delves into the critical role of early initiation of DAPT and explains the clinical importance of the NIH Stroke Scale (NIHSS) and the ABCD2 score in assessing patient risk and guiding therapy.
Early Initiation of Dual Antiplatelet Therapy
Clinical Evidence Supporting Early Initiation
CHANCE Study:
The CHANCE (Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events) trial is a landmark study that evaluated the effectiveness of dual antiplatelet therapy (DAPT) with clopidogrel plus aspirin versus aspirin alone in preventing recurrent stroke. This trial specifically targeted patients with acute minor ischemic stroke (NIHSS ≤3) or high-risk transient ischemic attack (TIA) (ABCD2 score ≥4) within 24 hours of symptom onset.
Patient Protocol:
A loading dose of clopidogrel (300 mg) was administered on day one, followed by 75 mg daily.
In addition, aspirin was given at a dose of 75 mg daily for the first 21 days, after which patients were continued on clopidogrel monotherapy (75 mg daily) for up to 90 days.
Key Finding: The early initiation of DAPT within 24 hours resulted in a 32% reduction in the risk of recurrent stroke compared to aspirin alone. Importantly, this benefit was achieved without a significant increase in hemorrhagic events within the first three months, demonstrating the safety and efficacy of early DAPT in this patient population.
POINT Study:
The POINT (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke) trial extended the findings of the CHANCE trial to a North American population. This study evaluated a higher clopidogrel loading dose (600 mg) followed by 75 mg daily, combined with aspirin (high dose initially, then tapered to a maintenance dose).
Key Finding: Similar to CHANCE, the POINT trial confirmed that early DAPT significantly reduced major vascular events, including recurrent stroke, when initiated within 24 hours of symptom onset. However, this trial also highlighted a slight increase in major bleeding, necessitating careful patient selection and monitoring during therapy.
Rationale for Early Administration
Acute Phase Vulnerability: The first 24 hours after an ischemic event is a critical period of vulnerability, during which the risk of stroke recurrence is high. Initiating DAPT early enhances platelet inhibition, reducing thrombus formation and stabilizing the vascular injury, thereby decreasing the likelihood of subsequent clot formation.
Pharmacodynamic Effects: Clopidogrel, when given as a loading dose, achieves effective platelet inhibition within hours, providing rapid protection against recurrent ischemic events. This quick onset of action is essential in the acute phase of stroke management.
Inclusion Criteria for the CHANCE Trial
A common question in clinical discussions is what makes a patient eligible for the CHANCE trial? Here are the key inclusion criteria:
Minor Ischemic Stroke:
Defined by a National Institutes of Health Stroke Scale (NIHSS) score of 3 or less. This indicates minimal neurological impairment, such as slight weakness or mild speech disturbances, but no major deficits.
High-Risk Transient Ischemic Attack (TIA):
Patients with a TIA who have an ABCD2 score of 4 or greater are considered high-risk. The ABCD2 score is calculated based on age, blood pressure, clinical symptoms, duration of symptoms, and diabetes status. A score of 4 or higher reflects a significant risk of stroke within 48 hours of the TIA.
Time Window:
Treatment must be initiated within 24 hours of the onset of symptoms, which underscores the importance of early recognition and rapid intervention in preventing further ischemic events.
Role of NIHSS and ABCD2 Scoring Systems
To optimize patient selection for DAPT, clinicians often rely on validated scoring systems like the NIH Stroke Scale (NIHSS) and the ABCD2 score, which help stratify risk and guide treatment decisions.
1. NIH Stroke Scale (NIHSS):
The NIHSS is a standardized tool used to assess the severity of a stroke and predict outcomes. It is widely used in both clinical and research settings to determine stroke severity and help guide treatment decisions, including the appropriateness of DAPT.
Components of NIHSS:
The scale includes 11 items, each evaluating a specific aspect of neurologic function, such as consciousness, gaze, visual fields, facial palsy, motor function of the arms and legs, limb ataxia, sensory loss, language, dysarthria, and extinction or inattention.
Each item is scored individually, and the total NIHSS score ranges from 0 to 42, with higher scores indicating more severe neurological impairment.
NIHSS and DAPT:
In the context of DAPT, a score of ≤3 on the NIHSS is considered a minor stroke, making the patient eligible for early dual antiplatelet therapy as indicated by studies like CHANCE and POINT.
2. ABCD2 Score:
The ABCD2 score is a clinical prediction tool used to estimate the risk of stroke following a transient ischemic attack (TIA). It helps identify high-risk patients who may benefit from more aggressive secondary prevention strategies, including DAPT.
Components of ABCD2:
Age: 1 point for age ≥60 years
Blood Pressure: 1 point for blood pressure ≥140/90 mmHg
Clinical Features: 2 points for unilateral weakness, 1 point for speech disturbance without weakness
Duration of Symptoms: 2 points for symptoms lasting ≥60 minutes, 1 point for symptoms lasting 10-59 minutes
Diabetes: 1 point for a history of diabetes
Scoring and Risk Stratification:
The total score ranges from 0 to 7. A score of 0-3 indicates low risk, 4-5 indicates moderate risk, and 6-7 indicates high risk for stroke within 2 days of a TIA.
ABCD2 and DAPT:
Patients with an ABCD2 score of 4 or higher are considered high-risk and are often recommended for DAPT if presenting with a TIA, based on evidence suggesting that this approach reduces the risk of subsequent stroke.
Practical Considerations and Guidelines
Guideline Recommendations:
The American Heart Association/American Stroke Association (AHA/ASA) guidelines recommend the use of DAPT (aspirin and clopidogrel) for up to 21 days in patients with minor stroke or high-risk TIA, followed by monotherapy due to the increased risk of hemorrhage with prolonged dual therapy.
Implementation in Clinical Practice:
Early Recognition and Action: It is essential to recognize eligible patients promptly and initiate DAPT within the first 24 hours to maximize the benefits.
Tailoring Therapy: Clinicians should use the NIHSS and ABCD2 scores to identify patients most likely to benefit from early DAPT while minimizing the risk of complications.
Monitoring and Adjustment: Patients on DAPT should be closely monitored for any signs of bleeding or other adverse effects, with therapy adjusted as needed based on the patient’s response and risk factors.
Step-by-Step Plan of Treatment for Acute Stroke Management
1. Control Risk Factors
1.1 Diabetes Mellitus (DM):
The goal is to maintain fasting blood sugar (FBS) <130 mg/dL and HbA1c <6.5% to ensure tight glucose control.
While hospitalized, aim to keep random blood sugar (RBS) between 140-180 mg/dL. This range prevents hyperglycemia-related complications and hypoglycemia, both of which can worsen neurological outcomes.
1.2 Hypertension (HT):
For acute ischemic stroke in a fast-track setting, the blood pressure (BP) should be controlled to <180/105 mmHg.
In non-fast track ischemic stroke, BP can be slightly higher, but should not exceed 220/120 mmHg.
In acute hemorrhagic stroke, the BP target is stricter at <140/90 mmHg.
Start with IV antihypertensives, such as Nicardipine or Labetalol drip, during the first 72 hours, then switch to oral antihypertensives as soon as possible.
Chronic HT management:
If the patient was well-controlled on oral antihypertensives, resume the previous regimen as soon as oral intake is feasible.
For poorly controlled or newly diagnosed HT, aim for a gradual BP reduction (no more than 15% in the first 24 hours). Start with low-dose, long-acting antihypertensives, such as:
Enalapril 5-10 mg/day (if GFR > 60)
Amlodipine 2.5 mg/day (if GFR < 60)
Atenolol 25 mg/day, Carvedilol 6.125 mg/day, or Metoprolol 25-50 mg/day (if heart rate >90 bpm)
Once the neurological condition stabilizes, target a BP of <140/90 mmHg or 130/80 mmHg for better outcomes.
Hypotension and Hypovolemia: Address these immediately to maintain adequate perfusion and organ function.
1.3 Dyslipidemia:
Control total cholesterol <200 mg/dL and LDL <70 mg/dL.
1.4 Atrial Fibrillation (AF):
Control heart rate and rhythm. If an echocardiogram hasn't been done, it should be performed within 1-2 months after the stroke stabilizes. Anticoagulation therapy should be considered based on stroke risk and AF pattern.
1.5 Smoking and Alcohol:
Stop smoking and reduce or eliminate alcohol intake to lower the risk of stroke recurrence.
2. Antiplatelet or Anticoagulants
2.1 Single Antiplatelet Therapy:
First choice: Aspirin starting at 300 mg daily for 2 weeks (1 grain = 64.79 mg but we make it easy to order 5 grains = 323.95 mg = ~300 mg), then switch to 81 mg daily for lifelong use, especially for TIA.
Second choice: Clopidogrel 75 mg daily if aspirin isn't tolerated.
Third choice: Cilostazol 100 mg twice daily for lifelong use if neither aspirin nor clopidogrel is suitable.
If the patient has been compliant with aspirin but still had an ischemic stroke (not caused by cardiac embolism), switch to clopidogrel.
2.2 Dual Antiplatelet Therapy (DAPT):
Based on the CHANCE study, DAPT is recommended for:
Minor ischemic stroke (NIHSS ≤3) or
High-risk TIA (ABCD2 score ≥4), started within 24 hours of symptom onset.
Day 1: Aspirin 300 mg + Clopidogrel 300 mg.
Day 2-21: Aspirin 81 mg + Clopidogrel 75 mg daily.
Day 22 onward:
Continue Aspirin 81 mg daily for life if the patient was not previously on aspirin.
Continue Clopidogrel 75 mg daily if the patient had been on aspirin prior to the stroke or is allergic to aspirin.
2.3 Anticoagulation for AF and Cardioembolic Stroke:
Focus on warfarin (target INR 2-3). Consider enoxaparin in the acute phase if needed, especially in cardioembolic strokes with large vessel involvement (e.g., basilar artery infarction).
Initiation of anticoagulation depends on stroke severity:
NIHSS <8 (mild stroke): Start anticoagulation after 3 days.
NIHSS 8-15 (moderate stroke): Start after 6 days.
NIHSS >15 (severe stroke): Start after 12 days.
For TIA from cardioembolic sources with AF, anticoagulation can begin after 1 day.
3. Hydration Management
For hypovolemia or normovolemia: Administer 0.9% NaCl at 80 mL/hr for 2-3 days.
For hypervolemia: Use 0.9% NaCl at 40 mL/hr for 1-2 days, and discontinue IV fluids once oral intake is sufficient.
4. Oxygen Supplementation
If O2 saturation drops below 94%, administer oxygen:
Nasal cannula at 1-3 LPM.
Oxygen mask with reservoir bag at 10 LPM.
5. Prevention of Complications
5.1 Fever Management:
If temperature >38°C, investigate for possible infections (e.g., pneumonia, UTI, phlebitis, cellulitis) and administer antipyretics like paracetamol.
5.2 Aspiration Precautions and Dysphagia Screening:
Perform a swallowing assessment before allowing oral intake of food or medications. If dysphagia is present:
Start enteral nutrition via NG or OG tube within 7 days.
If swallowing remains impaired beyond 2-3 weeks, consider a PEG tube.
5.3 Deep Vein Thrombosis (DVT) Prophylaxis:
In immobile patients, recommend intermittent pneumatic compression. Avoid prophylactic subcutaneous heparin unless necessary.
5.4 Seizure Precautions:
Avoid routine use of anticonvulsants for prophylaxis. If seizures occur, treat them accordingly.
6. Rehabilitation Therapy
Focus on motor function, balance, speech, and swallowing rehabilitation as early as possible to improve recovery outcomes.
7. Management of Hemorrhagic Stroke
For basal ganglion hemorrhage smaller than 2.5 cm, management is similar to ischemic stroke except:
Maintain BP <140/90 mmHg.
Elevate the head of the bed to 30 degrees.
Avoid anticoagulants or antiplatelets.
If the patient has coagulopathy or thrombocytopenia, correct these issues promptly.
Comentarios